- Home
- AAMI vs ZYME Comparison
AAMI vs ZYME Comparison
Compare AAMI & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AAMI | ZYME |
|---|---|---|
| Founded | 1980 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | AAMI | ZYME |
|---|---|---|
| Price | $72.30 | $24.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $58.00 | $38.90 |
| AVG Volume (30 Days) | 351.6K | ★ 550.2K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.61% | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $105,965,000.00 |
| Revenue This Year | $32.73 | $183.10 |
| Revenue Next Year | $14.44 | N/A |
| P/E Ratio | $23.86 | ★ N/A |
| Revenue Growth | N/A | ★ 38.87 |
| 52 Week Low | $29.26 | $11.61 |
| 52 Week High | $76.13 | $29.75 |
Technical Indicators
Market Signals| Indicator | AAMI | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 59.02 | 43.95 |
| Support Level | $46.04 | $22.28 |
| Resistance Level | $73.10 | $27.35 |
| Average True Range (ATR) | 2.49 | 1.02 |
| MACD | -0.12 | 0.04 |
| Stochastic Oscillator | 61.08 | 41.26 |
Price Performance
Historical ComparisonAbout AAMI Acadian Asset Management Inc.
Acadian Asset Management Inc is a holding company that operates a systematic investment management business through its subsidiary, that offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.